Regeneron Pharmaceuticals vs Universe Pharmaceuticals
REGN and UPC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How REGN and UPC compare
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus −22.4% for Universe Pharmaceuticals).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with −20.6% at Universe Pharmaceuticals.
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Universe Pharmaceuticals does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 5 for Universe Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | REGN | UPC |
|---|---|---|
| Size and price | ||
| Market cap | $98.8B | – |
| Share price | $955.47 | $1.51 |
| Change, 1 year | 40.2% | −59.0% |
| Change, 5 years | 46.4% | −100.0% |
| Beta (5Y) | 0.62 | 1.06 |
| Employees | 15K | 225 |
| StockData Score | ||
| Total score | 16 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 2 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 21.1× | – |
| P/S | 5.8× | – |
| P/B | 3.0× | – |
| EV/EBITDA | 17.0× | – |
| P/FCF | 25.8× | – |
| PEG | 7.63 | – |
| FCF yield | 3.9% | – |
| Fair value | $888.57 | – |
| Margin of safety | −7.5% | – |
| Growth | ||
| Revenue growth (TTM) | 18.6% (better) | −22.4% |
| Revenue growth, 5Y average | 11.0% | 257% (better) |
| Net income growth (TTM) | 5.2% | – |
| EPS growth (TTM) | 8.4% | – |
| EPS growth, 5Y average | 6.3% | – |
| Profitability | ||
| Gross margin | – | 35.3% |
| Operating margin | 28.8% (better) | −16.3% |
| Net margin | 28.5% (better) | −20.6% |
| FCF margin | 22.6% (better) | −29.8% |
| Return on equity | 14.9% (better) | −7261% |
| Return on invested capital | 16.3% (better) | −78.0% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.13 |
| Net debt / EBITDA | −1.36 | – |
| Interest coverage | 104× (better) | −10.1× |
| Current ratio | 3.35 | 4.05 (better) |
| Altman Z-score | 7.82 | – |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.39% | – |
| Payout ratio | 8.0% | – |
| Buyback yield | 2.0% | – |
| Shareholder yield | 2.4% | – |
| Ownership | ||
| Held by institutions | 88.5% | 6.6% |
| Held by insiders | 3.7% | – |
| Insider net buying, 12 months | −$57.4M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.2% | – |
Go deeper
- REGN stock overview
- REGN income statement
- REGN valuation and score
- UPC stock overview
- UPC income statement
- UPC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.